Reacción a "CAR-T therapy tested to treat childhood brain tumours considered incurable"

It is an important study for an indication for which, to date, there is no cure. Work like this, which is different from continuing to test small molecules or conventional chemotherapy, is very relevant.

It is a quality study. Stanford is a leading centre and the study is done with all the necessary quality parameters. They are not talking about an isolated case but about a regulated study that has passed several filters.

It is a different approach based on cell therapy and CARs, which have given very good results in haematological tumours but whose efficacy in solid tumours has yet to be demonstrated.

This is a phase I trial that shows that it is possible to approach this type of study in this type of patient. It also shows that we do not have to be afraid of toxicities if we have ways to manage them and they are accompanied by clinical improvement. Finally, the study indicates some efficacy, which opens the door to future trials and raises the need for combinations for this type of tumour.

The biggest limitation of this study is that patients were highly selected to have good performance status and tumours of adequate size. It will be interesting to see what happens with a more heterogeneous patient population.